In a first-in-human, phase I trial in patients with B-cell lymphoma,
CD19 CAR T cells with fully human binding domains exhibit lower neurologic toxicity,
but similar clinical activity, to previously tested CD19 CAR T cells with murine
binding domains.
- Jennifer N. Brudno
- Norris Lam
- James N. Kochenderfer